Photo ID and a full-body image are required for state-regulation identity verification. Treats patients 18 and older.
The FDA resolved the semaglutide shortage on April 22, 2025. Compounding is permitted only for individually identified patients when a prescribing practitioner determines that the compounded preparation produces a significant difference for their patient compared to the FDA-approved product.
General
Physicians review the online health assessment within about 24 hours. California, Massachusetts, Rhode Island, and Vermont route to a named physician and may require a video or audio consultation.